Which has higher valuation & earnings, INTS or FLNA?

Intensity Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Intensity Therapeutics N/A N/A -$11.61M -$3.57 N/A Cassava Sciences N/A N/A -$90.97M -$0.87 N/A

Is INTS or FLNA more profitable?

Cassava Sciences' return on equity of -58.78% beat Intensity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Intensity Therapeutics N/A -116.61% -94.01% Cassava Sciences N/A -58.78% -36.74%

Does the media prefer INTS or FLNA?

In the previous week, Cassava Sciences had 3 more articles in the media than Intensity Therapeutics. MarketBeat recorded 5 mentions for Cassava Sciences and 2 mentions for Intensity Therapeutics. Cassava Sciences' average media sentiment score of 0.32 beat Intensity Therapeutics' score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intensity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, INTS or GRCE?

Grace Therapeutics is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Intensity Therapeutics N/A N/A -$11.61M -$3.57 N/A Grace Therapeutics N/A N/A -$7.79M -$1.18 N/A

Is INTS or GRCE more profitable?

Grace Therapeutics' return on equity of -36.11% beat Intensity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Intensity Therapeutics N/A -116.61% -94.01% Grace Therapeutics N/A -36.11% -34.39%

Does the media prefer INTS or GRCE?

In the previous week, Intensity Therapeutics and Intensity Therapeutics both had 2 articles in the media. Grace Therapeutics' average media sentiment score of 0.91 beat Intensity Therapeutics' score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intensity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Grace Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is VERU or INTS more profitable?

Veru's return on equity of -47.58% beat Intensity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Intensity Therapeutics N/A -116.61% -94.01%

Does the media prefer VERU or INTS?

In the previous week, Veru had 1 more articles in the media than Intensity Therapeutics. MarketBeat recorded 3 mentions for Veru and 2 mentions for Intensity Therapeutics. Veru's average media sentiment score of 0.50 beat Intensity Therapeutics' score of 0.00 indicating that Veru is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veru 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intensity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is INTS or CRVO more profitable?

Intensity Therapeutics' return on equity of -116.61% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets Intensity Therapeutics N/A -116.61% -94.01% CervoMed N/A -156.02% -128.34%

Does the media prefer INTS or CRVO?

In the previous week, CervoMed had 2 more articles in the media than Intensity Therapeutics. MarketBeat recorded 4 mentions for CervoMed and 2 mentions for Intensity Therapeutics. Intensity Therapeutics' average media sentiment score of 0.00 equaled CervoMed'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intensity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CervoMed 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend INTS or AGFY?

Intensity Therapeutics currently has a consensus target price of $7.00, suggesting a potential upside of 92.84%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Intensity Therapeutics is more favorable than Agrify. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intensity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Agrify 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Intensity Therapeutics (INTS) Competitors

$3.63 -0.05 (-1.36%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.62 -0.01 (-0.28%)

As of 10/9/2026 07:30 PM Eastern

Compare

INTS vs. FLNA, GRCE, VERU, CRVO, and AGFY

Should you buy Intensity Therapeutics stock or one of its competitors? Intensity Therapeutics's main competitors and comparable companies include Cassava Sciences (FLNA), Grace Therapeutics (GRCE), Veru (VERU), CervoMed (CRVO), and Agrify (AGFY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Intensity Therapeutics compare to Cassava Sciences?

Intensity Therapeutics (NASDAQ:INTS) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

3.7% of Intensity Therapeutics shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 7.6% of Intensity Therapeutics shares are owned by insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Cassava Sciences had 3 more articles in the media than Intensity Therapeutics. MarketBeat recorded 5 mentions for Cassava Sciences and 2 mentions for Intensity Therapeutics. Cassava Sciences' average media sentiment score of 0.32 beat Intensity Therapeutics' score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intensity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Intensity Therapeutics presently has a consensus target price of $7.00, suggesting a potential upside of 92.84%. Cassava Sciences has a consensus target price of $5.00, suggesting a potential upside of 512.14%. Given Cassava Sciences' higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Intensity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Intensity Therapeutics has a beta of 2.81, suggesting that its stock price is 181% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.65, suggesting that its stock price is 165% less volatile than the broader market.

Cassava Sciences' return on equity of -58.78% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-116.61%	-94.01%
Cassava Sciences	N/A	-58.78%	-36.74%

Intensity Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$3.57	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

Summary

Cassava Sciences beats Intensity Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Intensity Therapeutics compare to Grace Therapeutics?

Intensity Therapeutics (NASDAQ:INTS) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

In the previous week, Intensity Therapeutics and Intensity Therapeutics both had 2 articles in the media. Grace Therapeutics' average media sentiment score of 0.91 beat Intensity Therapeutics' score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intensity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Grace Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grace Therapeutics is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$3.57	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A

Intensity Therapeutics currently has a consensus target price of $7.00, suggesting a potential upside of 92.84%. Grace Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 188.46%. Given Grace Therapeutics' higher probable upside, analysts plainly believe Grace Therapeutics is more favorable than Intensity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.7% of Intensity Therapeutics shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 7.6% of Intensity Therapeutics shares are held by company insiders. Comparatively, 10.8% of Grace Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Grace Therapeutics' return on equity of -36.11% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-116.61%	-94.01%
Grace Therapeutics	N/A	-36.11%	-34.39%

Intensity Therapeutics has a beta of 2.81, indicating that its share price is 181% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

Summary

Grace Therapeutics beats Intensity Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Intensity Therapeutics compare to Veru?

Veru (NASDAQ:VERU) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

In the previous week, Veru had 1 more articles in the media than Intensity Therapeutics. MarketBeat recorded 3 mentions for Veru and 2 mentions for Intensity Therapeutics. Veru's average media sentiment score of 0.50 beat Intensity Therapeutics' score of 0.00 indicating that Veru is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intensity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veru has a beta of -1.21, indicating that its stock price is 221% less volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.81, indicating that its stock price is 181% more volatile than the broader market.

47.2% of Veru shares are held by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are held by institutional investors. 14.2% of Veru shares are held by company insiders. Comparatively, 7.6% of Intensity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Veru presently has a consensus target price of $24.50, indicating a potential upside of 895.93%. Intensity Therapeutics has a consensus target price of $7.00, indicating a potential upside of 92.84%. Given Veru's higher possible upside, research analysts clearly believe Veru is more favorable than Intensity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Intensity Therapeutics has lower revenue, but higher earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.48	-$22.73M	-$0.69	N/A
Intensity Therapeutics	N/A	N/A	-$11.61M	-$3.57	N/A

Veru's return on equity of -47.58% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Intensity Therapeutics	N/A	-116.61%	-94.01%

Summary

Veru beats Intensity Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Intensity Therapeutics compare to CervoMed?

Intensity Therapeutics (NASDAQ:INTS) and CervoMed (NASDAQ:CRVO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

3.7% of Intensity Therapeutics shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 7.6% of Intensity Therapeutics shares are owned by company insiders. Comparatively, 35.8% of CervoMed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Intensity Therapeutics' return on equity of -116.61% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-116.61%	-94.01%
CervoMed	N/A	-156.02%	-128.34%

Intensity Therapeutics has a beta of 2.81, indicating that its stock price is 181% more volatile than the broader market. Comparatively, CervoMed has a beta of -0.75, indicating that its stock price is 175% less volatile than the broader market.

In the previous week, CervoMed had 2 more articles in the media than Intensity Therapeutics. MarketBeat recorded 4 mentions for CervoMed and 2 mentions for Intensity Therapeutics. Intensity Therapeutics' average media sentiment score of 0.00 equaled CervoMed'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intensity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CervoMed	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Intensity Therapeutics currently has a consensus target price of $7.00, suggesting a potential upside of 92.84%. CervoMed has a consensus target price of $21.00, suggesting a potential upside of 552.17%. Given CervoMed's higher probable upside, analysts clearly believe CervoMed is more favorable than Intensity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Intensity Therapeutics has higher earnings, but lower revenue than CervoMed. Intensity Therapeutics is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$3.57	N/A
CervoMed	$4.01M	12.14	-$26.97M	-$3.22	N/A

Summary

CervoMed beats Intensity Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Intensity Therapeutics compare to Agrify?

Intensity Therapeutics (NASDAQ:INTS) and Agrify (NASDAQ:AGFY) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

In the previous week, Intensity Therapeutics had 2 more articles in the media than Agrify. MarketBeat recorded 2 mentions for Intensity Therapeutics and 0 mentions for Agrify. Intensity Therapeutics' average media sentiment score of 0.00 equaled Agrify'saverage media sentiment score.

Company	Overall Sentiment
Intensity Therapeutics	Neutral
Agrify	Neutral

Intensity Therapeutics has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Intensity Therapeutics' return on equity of -116.61% beat Agrify's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-116.61%	-94.01%
Agrify	-424.11%	-185.90%	-72.67%

Intensity Therapeutics has higher earnings, but lower revenue than Agrify. Intensity Therapeutics is trading at a lower price-to-earnings ratio than Agrify, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$3.57	N/A
Agrify	$12.26M	3.19	-$41.75M	-$22.65	N/A

Intensity Therapeutics has a beta of 2.81, suggesting that its share price is 181% more volatile than the broader market. Comparatively, Agrify has a beta of 9.96, suggesting that its share price is 896% more volatile than the broader market.

Intensity Therapeutics currently has a consensus target price of $7.00, suggesting a potential upside of 92.84%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Intensity Therapeutics is more favorable than Agrify.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

3.7% of Intensity Therapeutics shares are held by institutional investors. Comparatively, 6.0% of Agrify shares are held by institutional investors. 7.6% of Intensity Therapeutics shares are held by company insiders. Comparatively, 2.2% of Agrify shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Intensity Therapeutics beats Agrify on 10 of the 15 factors compared between the two stocks.

Get Intensity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INTS vs. The Competition

Export

Metric	Intensity Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.02M	$12.35B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.36%
P/E Ratio	-1.02	797.58	274.15	26.16
Price / Sales	N/A	756.50	590.34	94.78
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	0.73	10.71	11.21	6.34
Net Income	-$11.61M	$2.84B	$3.50B	$381.90M
7 Day Performance	5.52%	-0.93%	-0.90%	-1.41%
1 Month Performance	-10.15%	-4.91%	-4.44%	-3.48%
1 Year Performance	-52.55%	-4.13%	6.96%	1.16%

Intensity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INTS Intensity Therapeutics	2.7086 of 5 stars	$3.63 -1.4%	$7.00 +92.8%	-54.1%	$12.02M	N/A	N/A	2,021
FLNA Cassava Sciences	3.463 of 5 stars	$0.89 -4.2%	$5.00 +464.3%	-80.5%	$44.67M	N/A	N/A	30
GRCE Grace Therapeutics	2.2038 of 5 stars	$2.15 +1.9%	$6.00 +179.1%	-31.1%	$44.39M	N/A	N/A	5	Positive News
VERU Veru	3.2634 of 5 stars	$2.66 +3.9%	$24.50 +821.1%	-42.5%	$43.65M	$16.89M	N/A	230	News Coverage Analyst Forecast
CRVO CervoMed	2.1375 of 5 stars	$2.97 +3.1%	$21.00 +607.1%	-62.3%	$43.54M	$4.01M	N/A	15	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INTS) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intensity Therapeutics (INTS) Competitors

INTS vs. FLNA, GRCE, VERU, CRVO, and AGFY

How does Intensity Therapeutics compare to Cassava Sciences?

Summary

How does Intensity Therapeutics compare to Grace Therapeutics?

Summary

How does Intensity Therapeutics compare to Veru?

Summary

How does Intensity Therapeutics compare to CervoMed?

Summary

How does Intensity Therapeutics compare to Agrify?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTS vs. The Competition

Intensity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intensity Therapeutics (INTS) Competitors

INTS vs. FLNA, GRCE, VERU, CRVO, and AGFY

How does Intensity Therapeutics compare to Cassava Sciences?

Do institutionals & insiders hold more shares of INTS or FLNA?

Does the media prefer INTS or FLNA?

Do analysts rate INTS or FLNA?

Which has more volatility and risk, INTS or FLNA?

Is INTS or FLNA more profitable?

Which has higher valuation & earnings, INTS or FLNA?

Summary

How does Intensity Therapeutics compare to Grace Therapeutics?

Does the media prefer INTS or GRCE?

Which has better valuation and earnings, INTS or GRCE?

Do analysts rate INTS or GRCE?

Do institutionals and insiders have more ownership in INTS or GRCE?

Is INTS or GRCE more profitable?

Which has more volatility and risk, INTS or GRCE?

Summary

How does Intensity Therapeutics compare to Veru?

Does the media prefer VERU or INTS?

Which has more risk & volatility, VERU or INTS?

Do insiders and institutionals hold more shares of VERU or INTS?

Do analysts rate VERU or INTS?

Which has higher earnings and valuation, VERU or INTS?

Is VERU or INTS more profitable?

Summary

How does Intensity Therapeutics compare to CervoMed?

Do institutionals and insiders hold more shares of INTS or CRVO?

Is INTS or CRVO more profitable?

Which has more volatility & risk, INTS or CRVO?

Does the media prefer INTS or CRVO?

Do analysts recommend INTS or CRVO?

Which has better earnings and valuation, INTS or CRVO?

Summary

How does Intensity Therapeutics compare to Agrify?

Does the media favor INTS or AGFY?

Is INTS or AGFY more profitable?

Which has better earnings and valuation, INTS or AGFY?

Which has more volatility and risk, INTS or AGFY?

Do analysts recommend INTS or AGFY?

Do institutionals & insiders have more ownership in INTS or AGFY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTS vs. The Competition

Intensity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools